Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Revolo and Northway Biotech Enter Manufacturing Partnership | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Revolo and Northway Biotech Enter Manufacturing Partnership

To manufacture novel binding immunoglobulin protein, ‘1805, to support phase 2 trials in rheumatoid arthritis and uveitis.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Revolo Biotherapeutics has entered into a partnership with Northway Biotech, a global end-to-end biopharmaceutical contract development and manufacturing organization (CDMO), to manufacture its binding immuno-regulatory protein, ‘1805.
 
Northway will provide the full scope of its services ranging from cell line development to batch production of ‘1805 active pharmaceutical ingredients (API) and drug product, following current good manufacturing practices (cGMP), with quality assurance and regulatory compliance support.
 
“Northway is the ideal partner for our manufacturing needs,” said Jonathan Rigby, CEO, Revolo Biotherapeutics. “Their expertise in cell fermentation, protein characterization and global outreach will enable our upcoming phase 2 clinical trials for ‘1805. The close collaboration between the two organizations will provide a seamless progression from our current drug supply and future process and formulation advancements.”
 
Vladas Algirdas Bumelis, CEO, Northway Biotech, said, “We are excited to announce our partnership with Revolo Biotherapeutics for the development and manufacturing of ‘1805. Northway Biotech’s global teams in Waltham, MA (U.S.), and Vilnius, Lithuania will closely collaborate with Revolo Biotherapeutics to expedite success in bringing this first-in-class therapy for patients with rheumatoid arthritis and non-infectious uveitis to market quickly and efficiently.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics